Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1997 Oct;63(4):434–440. doi: 10.1136/jnnp.63.4.434

Hallucinosis in idiopathic Parkinson's disease

J Graham 1, R Grunewald 1, H Sagar 1
PMCID: PMC2169767  PMID: 9343119

Abstract

BACKGROUND—Hallucinosis is a complication of the treatment of idiopathic Parkinson's disease commonly thought to afflict older, chronically medicated, cognitively impaired patients. However, patients with idiopathic Parkinson's disease of short duration experiencing hallucinosis on relatively low doses of dopaminergic medication have been found. The aim, therefore, was to investigate the homogeneity of a population of patients with idiopathic Parkinson's disease and hallucinosis.
METHODS—The clinical, demographic, and cognitive correlates of hallucinosis were investigated in a sample of 129 patients with idiopathic Parkinson's disease.
RESULTS—There were two subgroups of patients with idiopathic Parkinson's disease experiencing hallucinosis. In patients with a disease duration of five years or less, hallucinosis was associated with rapid progression of the motor component of the disease but not cognitive impairment. In patients with idiopathic Parkinson's disease of longer than five years duration, hallucinosis was associated with postural instability, global cognitive impairment, and lack of depressive affect. In all patients with idiopathic Parkinson's disease, hallucinosis was more prevalent when they were treated with a direct acting dopamine receptor agonist. Hallucinosis was not associated with age at onset of idiopathic Parkinson's disease or dosage of dopaminergic medication.
CONCLUSION—Hallucinosis in idiopathic Parkinson's disease is heterogeneous, falling into two groups. The difference in the pathophysiological basis of hallucinosis in these two groups of patients is discussed.



Full Text

The Full Text of this article is available as a PDF (151.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexopoulos G. S., Abrams R. C., Young R. C., Shamoian C. A. Cornell Scale for Depression in Dementia. Biol Psychiatry. 1988 Feb 1;23(3):271–284. doi: 10.1016/0006-3223(88)90038-8. [DOI] [PubMed] [Google Scholar]
  2. BECK A. T., WARD C. H., MENDELSON M., MOCK J., ERBAUGH J. An inventory for measuring depression. Arch Gen Psychiatry. 1961 Jun;4:561–571. doi: 10.1001/archpsyc.1961.01710120031004. [DOI] [PubMed] [Google Scholar]
  3. Blessed G., Tomlinson B. E., Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968 Jul;114(512):797–811. doi: 10.1192/bjp.114.512.797. [DOI] [PubMed] [Google Scholar]
  4. Cooper J. A., Sagar H. J., Jordan N., Harvey N. S., Sullivan E. V. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain. 1991 Oct;114(Pt 5):2095–2122. doi: 10.1093/brain/114.5.2095. [DOI] [PubMed] [Google Scholar]
  5. Cummings J. L. Behavioral complications of drug treatment of Parkinson's disease. J Am Geriatr Soc. 1991 Jul;39(7):708–716. doi: 10.1111/j.1532-5415.1991.tb03627.x. [DOI] [PubMed] [Google Scholar]
  6. Daniel S. E., Lees A. J. Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl. 1993;39:165–172. [PubMed] [Google Scholar]
  7. Danielczyk W. Mental disorders in Parkinson's disease. J Neural Transm Suppl. 1992;38:115–127. [PubMed] [Google Scholar]
  8. Downes J. J., Roberts A. C., Sahakian B. J., Evenden J. L., Morris R. G., Robbins T. W. Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: evidence for a specific attentional dysfunction. Neuropsychologia. 1989;27(11-12):1329–1343. doi: 10.1016/0028-3932(89)90128-0. [DOI] [PubMed] [Google Scholar]
  9. Factor S. A., Molho E. S., Podskalny G. D., Brown D. Parkinson's disease: drug-induced psychiatric states. Adv Neurol. 1995;65:115–138. [PubMed] [Google Scholar]
  10. Fischer P., Danielczyk W., Simanyi M., Streifler M. B. Dopaminergic psychosis in advanced Parkinson's disease. Adv Neurol. 1990;53:391–397. [PubMed] [Google Scholar]
  11. Goetz C. G., Tanner C. M., Klawans H. L. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry. 1982 Apr;139(4):494–497. doi: 10.1176/ajp.139.4.494. [DOI] [PubMed] [Google Scholar]
  12. Hippius H. The history of clozapine. Psychopharmacology (Berl) 1989;99 (Suppl):S3–S5. doi: 10.1007/BF00442551. [DOI] [PubMed] [Google Scholar]
  13. Lauterbach E. C. Serotonin reuptake inhibitors, paranoia, and the ventral basal ganglia. Clin Neuropharmacol. 1991 Dec;14(6):547–555. doi: 10.1097/00002826-199112000-00007. [DOI] [PubMed] [Google Scholar]
  14. Meco G., Bonifati V., Cusimano G., Fabrizio E., Vanacore N. Hallucinations in Parkinson disease: neuropsychological study. Ital J Neurol Sci. 1990 Aug;11(4):373–379. doi: 10.1007/BF02335940. [DOI] [PubMed] [Google Scholar]
  15. Moskovitz C., Moses H., 3rd, Klawans H. L. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry. 1978 Jun;135(6):669–675. doi: 10.1176/ajp.135.6.669. [DOI] [PubMed] [Google Scholar]
  16. Nausieda P. A., Weiner W. J., Kaplan L. R., Weber S., Klawans H. L. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol. 1982;5(2):183–194. doi: 10.1097/00002826-198205020-00003. [DOI] [PubMed] [Google Scholar]
  17. Nelson H. E., O'Connell A. Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test. Cortex. 1978 Jun;14(2):234–244. doi: 10.1016/s0010-9452(78)80049-5. [DOI] [PubMed] [Google Scholar]
  18. Owen A. M., Downes J. J., Sahakian B. J., Polkey C. E., Robbins T. W. Planning and spatial working memory following frontal lobe lesions in man. Neuropsychologia. 1990;28(10):1021–1034. doi: 10.1016/0028-3932(90)90137-d. [DOI] [PubMed] [Google Scholar]
  19. Rondot P., de Recondo J., Coignet A., Ziegler M. Mental disorders in Parkinson's disease after treatment with L-DOPA. Adv Neurol. 1984;40:259–269. [PubMed] [Google Scholar]
  20. Sahakian B. J., Morris R. G., Evenden J. L., Heald A., Levy R., Philpot M., Robbins T. W. A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease. Brain. 1988 Jun;111(Pt 3):695–718. doi: 10.1093/brain/111.3.695. [DOI] [PubMed] [Google Scholar]
  21. Sanchez-Ramos J. R., Ortoll R., Paulson G. W. Visual hallucinations associated with Parkinson disease. Arch Neurol. 1996 Dec;53(12):1265–1268. doi: 10.1001/archneur.1996.00550120077019. [DOI] [PubMed] [Google Scholar]
  22. Wolters E. C., Jansen E. N., Tuynman-Qua H. G., Bergmans P. L. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology. 1996 Oct;47(4):1085–1087. doi: 10.1212/wnl.47.4.1085. [DOI] [PubMed] [Google Scholar]
  23. Zoldan J., Friedberg G., Livneh M., Melamed E. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology. 1995 Jul;45(7):1305–1308. doi: 10.1212/wnl.45.7.1305. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES